SOURCE: Gene Express, Inc.

October 30, 2006 08:58 ET

Gene Express Appoints John Anders, Ph.D. Vice President of Operations

Capitalizes on 26 Years of Drug Development Expertise

TOLEDO, OH -- (MARKET WIRE) -- October 30, 2006 -- Gene Express, Inc. today announced the appointment of John C. Anders, Ph.D. as Vice President of Operations.

Gerald Vardzel, CEO of Gene Express, commented, "We are pleased to have the benefit of Dr. Anders' hands-on managerial experience as Gene Express expands to meet the demand of our growing customer and partner base. His technical expertise will serve us well as we progress our internal research efforts and establish additional high throughput Standardized Expression Measurement (SEM) Centers™ for our customers."

Dr. Anders has spent 26 years in the drug development sector for both small and large molecules in both government and private sector scientific organizations. Prior to joining Gene Express, Dr. Anders held various positions from Senior Scientist to Director in the Biotechnology Laboratory at AAI Pharma, where he was responsible for building and staffing a state of the art cGMP Biotechnology analytical lab. In addition, Dr. Anders was charged with characterization and release of marketed products and development of investigational drugs in all phases of development.

From 1991 to 1993, Major Anders, Ph.D. served as the Chief of Applied Pharmacology Branch at the U.S. Army Medical Research Institute of Chemical Defense. During his tenure, he led a staff of 19 military and civilian personnel in the research and development of various antidotal and pretreatment regimes against chemical warfare agents. Prior to this, Dr. Anders served in various capacities at the Walter Reed Army Institute of Research developing anti-malarial drugs and vaccines. Dr. Anders has authored and co-authored more than 20 publications and abstracts.

Dr. Anders said, "My background in addressing the challenges of drug research and development leads me to believe strongly in the value proposition offered by Gene Express' StaRT-PCR™ technology. I look forward to contributing to the Company's growth."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact